Facilitated Telemedicine in the Catholic Health System
Launched by STATE UNIVERSITY OF NEW YORK AT BUFFALO · Jun 25, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Facilitated Telemedicine in the Catholic Health System" is focused on improving the treatment of Hepatitis C virus (HCV), which is a serious health issue, especially among people dealing with opioid use. The goal of this study is to see how well telemedicine—using technology to provide healthcare remotely—can help people start and finish their treatment for HCV at three opioid treatment programs run by the Catholic Health System. Researchers will review patient records to understand how effective this approach is in helping patients with HCV.
To be eligible for the trial, participants need to have a confirmed active HCV infection. The study is open to all genders and is aimed at individuals aged 65 to 74. While the trial is not yet recruiting participants, those who take part can expect to receive care through telemedicine, which may offer them more convenient access to treatment. Overall, this trial is an important step toward making HCV treatment more accessible for vulnerable populations.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • evidence of active HCV infection
- Exclusion Criteria:
- • no evidence of active HCV infection
About State University Of New York At Buffalo
The State University of New York at Buffalo (SUNY Buffalo) is a prominent research institution dedicated to advancing healthcare through innovative clinical trials and studies. Renowned for its commitment to academic excellence and interdisciplinary collaboration, the university leverages its extensive resources and expertise to explore novel therapeutic approaches and enhance patient outcomes. SUNY Buffalo's clinical trials encompass a wide range of medical disciplines, driven by a mission to translate research discoveries into practical applications that benefit diverse populations. With a focus on ethical standards and rigorous methodologies, the university fosters an environment that supports cutting-edge research while prioritizing participant safety and well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Andrew H Talal, MD, MPH
Principal Investigator
University at Buffalo
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported